Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 1059S

1059S 100 µg

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Immunohistochemical analysis of paraffin-embedded human breast carcinoma using HER2/ErbB2 (29D8) Rabbit mAb #2165 in the presence of control peptide (left) or HER2/ErbB2 Blocking Peptide (right).

Learn more about how we get our images
Image

Product Description

This peptide is used to block HER2/ErbB2 (29D8) Rabbit mAb #2165 reactivity in immunohistochemistry protocols.


Quality Control

The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry. The peptide blocks HER2/ErbB2 (29D8) Rabbit mAb #2165 signal in immunohistochemistry.

Product Usage Information

Use as a blocking reagent to evaluate the specificity of antibody reactivity in immunohistochemistry protocols. For immunohistochemistry, add twice the volume of peptide as volume of antibody used in 100 μl total volume. Incubate for a minimum of 30 minutes prior to adding the entire volume to the slide. Recommended antibody dilutions can be found on the product data sheet.


Storage: Supplied in 20 mM potassium phosphate (pH 7.0), 50 mM NaCl, 0.1 mM EDTA, 1 mg/ml BSA and 5% glycerol. Store at –20°C.

The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity (1). While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members (2). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers (3). Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase (4). ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway (1,5).


1.  Muthuswamy, S.K. et al. (1999) Mol Cell Biol 19, 6845-57.

2.  Qian, X. et al. (1994) Proc Natl Acad Sci USA 91, 1500-4.

3.  Dittadi, R. and Gion, M. (2000) J Natl Cancer Inst 92, 1443-4.

4.  Klapper, L.N. et al. (2000) Cancer Res 60, 3384-8.

5.  Kwon, Y.K. et al. (1997) J Neurosci 17, 8293-9.


Entrez-Gene Id 2064
Swiss-Prot Acc. P04626


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.